Interleukin 11 (IL-11) is a pleiotropic cytokine with biological activities on many different cell types. Recombinant human IL-11 (rhIL-11) is produced by recombinant DNA technology in Escherichia coli. Both in vitro and in vivo, rhIL-11 has shown effects on multiple hematopoietic cell types. Its predominant in vivo hematopoietic activity is the stimulation of peripheral platelet counts in both normal and myelosuppressed animals. This activity is mediated through effects on both early and late progenitor cells to stimulate megakaryocyte differentiation and maturation. rhIL-11 has been approved for the treatment of chemotherapy-induced thrombocytopenia. The hematopoietic effects of rhIL-11 are most likely direct effects on progenitor cells and megakaryocytes in combination with other cytokines or growth factors. rhIL-11 also induces secretion of acute phase proteins (ferritin, haptoglobin, C-reactive protein, and fibrinogen) from the liver. The induction of heme oxidase and inhibition of several P450 oxidases have been reported from in vitro studies. In vivo, rhIL-11 treatment decreases sodium excretion by the kidney by an unknown mechanism and induces hemodilution. rhIL-11 also exhibits anti-inflammatory effects in a variety of animal models of acute and chronic inflammation, including inflammatory bowel disease, inflammatory skin disease, autoimmune joint disease, and various infection-endotoxemia syndromes. rhIL-11 has trophic effects on non-transformed intestinal epithelium under conditions of mucosal damage. The mechanism of the anti-inflammatory activity of rhIL-11 has been extensively studied. rhIL-11 directly affects macrophage and T cell effector function. rhIL-11 inhibits tumor necrosis factor-alpha (TNF␣), interleukin 1␤ (IL-1␤), interleukin 12 (IL-12), interleukin 6 (IL-6), and nitric oxide (NO) production from activated macrophages in vitro. The inhibition of cytokine production was associated with inhibition of nuclear translocation of the transcription factor, nuclear factor kappa B (NF-B) . The block to NF-B nuclear translocation correlates with the ability of rhIL-11 to maintain or enhance production of the inhibitors of NF-B, IB-␣ and IB-␤. In addition to effects on macrophages, rhIL-11 also reduces CD4 ؉ T cell production of Th1 cytokines, such as IFN␥ induced by IL-12, while enhancing Th2 cytokine production. rhIL-11 also blocks IFN␥ production in vivo. The molecular effects of rhIL-11 have also been studied in a clinical trial. Molecular analysis of skin biopsies of patients with psoriasis before and during rhIL-11 treatment demonstrates a decrease in mRNA levels of TNF␣, IFN␥ and iNOS. These activities suggest that in addition to its thrombopoietic clinical use, rhIL-11 may also be valuable in the treatment of inflammatory diseases. The clinical utility of the anti-inflammatory properties of rhIL-11 is being investigated in patients with Crohn's disease, psoriasis and rheumatoid arthritis. These diseases are believed to be initiated and maintained by activated CD4 ؉ Th1 cells in conjunction with activated macrophages.
Introduction
Interleukin 11 (IL-11) is a cytokine first identified as an activity in an immortalized primate bone marrow stromal cell line and cloned from a human fetal lung fibroblast cell line.
1,2 The human IL-11 complementary DNA (cDNA) encodes a protein of 199 amino acids with a leader sequence of 21 AA and a molecular mass of 19 kDa. The secreted protein has 178 amino acids, is monomeric, and exhibits a pI Ͼ11. IL-11 interacts with its ligand-specific cell surface receptor subunit (IL-11R␣) that is coupled to a signal transducing subunit, gp130. 3 IL-11 is a member of a family of cytokines, including IL-6, LIF, Oncostatin M, CT-1 and CNTF that utilizes gp130 as the signal transducing subunit of the receptor complex and, thus, exhibit some overlapping activities. IL-11R␣ is found on numerous tissues. 4 ,5 IL-11 mRNA expression is also ubiquitous, but blood IL-11 levels are rarely detected. [6] [7] [8] Interleukin-11 is a pleiotropic cytokine that displays diverse effects such as stimulation of myeloid, erythroid and megakaryocyte differentiation as well as modulation of macrophage and T cell inflammatory function and induction of the hepatic acute phase response.
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IL-11 gene structure
The genomic sequence for IL-11 is contained on a 7 kb fragment. The human gene consists of five exons and four introns and maps to human chromosome 19q13. 3-19q13.4 . 11 The IL-11 promoter contains consensus nucleotide binding sites for transcription factors AP-1, SP-1, CTF/NF-1 and EF/C. In addition, interferon-inducible and phorbol-ester-inducible elements have been localized to the 5Ј region of the gene. A putative NF-B binding element has been localized 720 bp upstream of the mRNA start site. 12 Two polyadenylation signals have been identified at the 3Ј end of the gene leading to the production of two transcripts that differ only in the 3Ј untranslated sequences.
IL-11 protein
Structurally, IL-11 is unrelated to any other cytokine and displays a number of distinct protein features such as an absence of cysteine residues, asparagine-linked glycosylation sites, and O-linked glycosylation. IL-11 is rich in proline (12%), leucine (23%) and other positively charged residues (14%), resulting in a highly basic protein with an isoelectric point of Ͼ11. Recombinant human IL-11 (rhIL-11) is manufactured in E. coli and differs from the naturally occurring molecule in the absence of the amino terminal proline residue.
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Gene expression
Little is known regarding regulation of IL-11 expression in vivo. Analysis of normal adult murine tissue indicates the presence of low levels of IL-11 mRNA in the thymus, spleen, bone marrow, heart, lung, small and large intestine, kidney, brain, testis and ovary. 4, 15 In situ hybridization has localized IL-11 expression to the middle cellular layers of the seminiferous tubules of the testis and the hippocampus and ventral area of the spinal cord. 15 Detection of IL-11 in the blood of humans or animals is rare, suggesting that synthesis and secretion occur at a low level. Alternatively, because of its highly basic nature, IL-11 may bind to extracellular matrix and remain localized near the cellular site of synthesis.
IL-11 receptor
The IL-11 receptor complex consists of the ligand binding ␣ chain and the signal transducing subunit, gp130.
5 IL-11 shares the utilization of gp130 with IL-6, LIF, Oncostatin M and CNTF which results in partly overlapping activities.
3 IL-11R␣ chain consists of an extracellular domain, containing two potential N-linked glycosylation sites, a transmembrane domain, and a cytoplasmic tail. 5, 16, 17 Primary amino acid comparisons indicate that IL-11R␣ is most closely related to IL-6R␣ chain (24% amino acid homology) and CNTF receptor ␣ chain (22% amino acid homology). The extracellular domain contains structural features characteristic of hematopoietic receptors such as proline residues preceding each 100 amino acid subdomain, a motif of four conserved cysteines and one tryptophan residue, a series of polar and hydrophobic amino acid residues, and the WSXWS domain between the cysteine and transmembrane domain.
The genomic structure of the murine IL-11R␣ consists of 14 exons with alternative use of the first two exons being developmentally regulated. 18 More recently, a second murine IL-11R␣ locus has been identified (IL-11R␣ 2) adjacent to the IL-11R␣ 1 gene. 19 It shares 99% sequence identity with IL-11R␣ 1 in the coding exons but contains differences in the 5Ј untranslated region (5ЈUTR). The murine IL-11R␣ 1 gene is expressed at relatively low abundance in a broad spectrum of tissues including bone marrow, spleen, thymus, lung, bladder, heart, brain, kidney, muscle, salivary gland, small and large intestine, ovary, testis and uterus as well as a number of primary cell types such as macrophages, osteoblasts and osteoclasts. 4, 20, 21 Expression of the IL-11R␣ 2 gene is restricted to the testis, lymph node and thymus. 19 The human IL-11R␣ chain shares 85% nucleotide identity and 84% amino acid identity with the murine genes. 17, 22 Its genomic structure consists of 12 exons contained on a 9-kb region and is located on chromosome 9 band 9p13. 23 Two isoforms of the human ␣ chain have been identified which differ in the structure of their cytoplasmic domains. 24 One isoform has a short cytoplasmic domain similar to the IL-6R␣ and murine IL-11R␣ chains. The second isoform lacks the cytoplasmic domain and is more similar to the human CNTF receptor (CNTFR). The structural similarities between the ␣ chains of IL-11R and CNTFR suggest that they may have evolved from a common ancestor. A transcript encoding a soluble form of IL-11R␣ has been identified, no soluble IL-11R␣ protein has been found. 25 The IL-11R␣ chain does not have to be membrane bound to elicit a biological effect because recombinant soluble forms of the ␣-chain receptor have been generated in vitro that can bind IL-11 and activate gp130. 26 IL-11 binding to the IL-11R␣ chain alone occurs with low affinity (kd ෂ 10 nM) and is insufficient to transduce a signal. A high affinity receptor complex capable of transducing a signal (kd ෂ400-800 pM) is generated upon co-expression of IL-11R␣ and gp130. 5, 27 The stoichiometry of the high affinity IL-11R complex is at present unknown. Recent evidence from in vitro solution phase binding assays indicates that the high affinity IL-6R consists as a hexameric complex of two IL-6 molecules, two IL-6R␣ chains, and a gp130 homodimer. A similar hexameric complex has also been proposed for the CNTFR complex, with the exception of a heterodimer of gp130 and the LIFR ␣ chain replacing the gp130 homodimer. Similar studies examining the IL-11R complex indicate a dimer of IL-11 and IL-11R␣ forms in the presence of gp130, resulting in a pentameric complex. However, homodimerization of gp130 or heterodimerization of gp130 and LIFR did not occur. 26 These studies suggest an as yet unidentified IL-11R ␣-chain involved in IL-11 signal transduction.
Biological functions essential to IL-11 have been investigated through the generation of mice with a null mutation of the IL-11R ␣-chain gene (IL-11R␣−/−). [28] [29] [30] IL-11R␣−/− mice were healthy and had normal peripheral white blood cell, hematocrit and platelet levels. 28 However, female mice were infertile because of defective decidualization. 29, 30 Thus, similar to LIF, IL-11 appears to play a critical role during reproduction. Together, these ligands comprise a family of structurally related proteins that share many overlapping functional properties because of a shared receptor signaling complex.
Regulation of IL-11 secretion
IL-11 protein secretion and/or gene expression is induced by IL-1␣, TNF-␣, TGF-␤, prostaglandin E 2 (PGE 2 ), parathyroid hormone, 1,25-dihydroxyvitamin D 3 , phorbol myristate acetate (PMA), the calcium ionophore A23187, and a variety of viruses (such as respiratory syncytial, parainfluenza and rhinovirus) in cells primarily of mesenchymal origin. [31] [32] [33] [34] IL-11 expression has been detected in a number of in vitro cell culture assays, including fibroblasts, chondrocytes, synoviocytes, osteoblasts and trophoblasts. [35] [36] [37] Endogenous IL-11 protein levels Endogenous IL-11 plasma or serum concentrations are undetectable or at very low levels in normal volunteers or patients undergoing bone marrow transplantation. 6, 38 It has also been concluded that circulating levels of IL-11 do not contribute to a major extent to liver acute phase protein production. 39 IL-11 has been found in synovial fluid and in human ovarian follicular fluid. 7 The function of IL-11 in these compartments has been linked to its anti-inflammatory activity and involvement in follicular maturation.
Hematopoietic effects of IL-11
In vitro hematopoietic effects
Early studies demonstrated the hematopoietic effects of rhIL-11 in an in vitro blast colony assay to enhance the number of blast cell colonies. 40, 41 In synergy with other early acting hematopoietic growth factors such as IL-3, IL-4 or stem cell factor, IL-11 can trigger division of quiescent primitive progenitor cells by stimulating exit from the G 0 phase and the entry into G 1 /S phase of the cell cycle. IL-11 also has direct effects on megakaryocytes (MK) and MK precursors in vitro. 42 In synergy with IL-3, IL-11 enhanced both murine and human MK colony formation. These in vitro studies have indicated that rhIL-11 acts on both early-and late-stage progenitor cells to promote megakaryocyte differentiation and maturation. rhIL-11 also stimulates erthyropoiesis and lymphopoiesis in vitro. In synergy with Steel Factor and erthyropoietin, rhIL-11 stimulated early stage erythroid burst formation. 43 In combination with IL-3, rhIL-11 stimulated the development of hemoglobinized bursts, indicating effects on late stage erythroid development. rhIL-11 has been shown to stimulate antibody producing B cells in an accessory cell-dependent manner. 44 
In vivo hematopoietic effects
In all species tested (mouse, rat, dog, hamster and nonhuman primate), rhIL-11 increased peripheral platelet counts when administered as a single agent to normal animals. [45] [46] [47] Normal mice and rats administered rhIL-11 for 7 days, had a 30% to 50% elevation in peripheral platelets. Studies in nonhuman primates also showed that rhIL-11 increased peripheral platelet counts. In rhIL-11-treated cynomolgus monkeys, bone marrow megakaryocytes appeared to be mature and ultrastructurally normal. 48 These animal studies indicate that one of the predominant in vivo effects of rhIL-11 is the stimulation of multiple phases of megakaryocytopoiesis and thrombopoiesis.
In murine models of chemotherapy-and/or irradiationinduced myelosuppression or bone marrow transplantation subsequent to myeloablation, administration of rhIL-11 stimulated megakaryocytopoiesis, thrombopoiesis, and multilineage recovery of hematopoietic progenitor cells. 49 In addition, in a carboplatin model of myelosuppression in cynomolgus monkeys, once daily treatment with rhIL-11 improved platelet nadirs and accelerated platelet recovery compared with control animals. 45, 50 The multilineage stimulation of rhIL-11 in these myeloablated animals probably represents synergy with endogenous cytokines, induced by the myeloablative regimens. Taken together, these observations suggest that normal physiological processes of megakaryocyte development and thrombopoiesis were induced by rhIL-11.
Clinical cancer support therapies
The use of rhIL-11 as a supportive therapy for the prevention of severe thrombocytopenia following cancer chemotherapy has been evaluated in several clinical trials. The results indicate that rhIL-11 treatment produced a dose-dependent increase in peripheral platelets, which reduced the need for platelet transfusions. 51, 52 As a result of these trials, rhIL-11 is currently marketed (Neumega; Genetics Institute, Andover, MA, USA) for the treatment of chemotherapy-induced thrombocytopenia. The clinical experience indicates that about 1% of patients treated with Neumega develop antibodies, with no noticeable impact on its activity, thus these antibodies seem to be non-neutralizing. Based on its effects on damaged epithelium (as described in the next section), rhIL-11 is also currently under investigation for the treatment of mucositis. 53 
Platelet growth dynamics
A phase I study in patients with breast cancer showed that treatment with rhIL-11 before chemotherapy resulted in a dose-dependent increase in platelet levels. 51 Following a small decrease (probably due to hemodilution caused by rhIL-11), platelet levels rose above baseline 5 days after the start of treatment and continued to rise throughout the 14-day treatment period. At doses of 10, 25, 50 and 75 g/kg, platelet levels achieved maximum levels 76, 93, 108 and 186% above baseline at a median 18, 19, 16 and 14 days, respectively, after the start of treatment. rhIL-11 resulted in no apparent changes in platelet function. In a study of the efficacy of rhIL-11 for prevention of severe chemotherapy-induced thrombocytopenia, patients treated daily with 50 g/kg rhIL-11 following chemotherapy were significantly less likely to require a platelet transfusion than those treated with placebo. 52 Kinetic analysis of platelet profiles 54 suggested that treatment with rhIL-11 had no effect on average platelet lifetime but resulted in higher predicted platelet nadirs (21 ±
Epithelial effects
Epithelial cells in vitro
rhIL-11 directly interacts with intestinal epithelial cells to inhibit proliferation in vitro. 55, 56 Treatment of rat intestinal epithelial cell lines (IEC-6 and IEC-18) with rhIL-11 resulted in inhibition of proliferation. Growth inhibition correlated with delayed entry into the S phase of the cell cycle and suppression of retinoblastoma protein (pRB) phosphorylation. 56 These studies indicate that rhIL-11 can directly affect intestinal epithelial cells.
In vivo models of epithelial damage
In a murine model of combined chemotherapy and radiation in which death occurred from sepsis secondary to gastrointestinal damage, rhIL-11 treatment ameliorated small intestinal damage and increased survival. 57 In a follow-up study, animals treated with rhIL-11 showed reduced apoptosis and increased mitosis in the small intestine, which was associated with mucosal recovery from cytoablative damage. 58 In a hamster model of 5-FU-induced oral mucositis, administration of rhIL-11 reduced the severity, frequency, and duration of oral mucositis. 59, 60 Taken together, these studies suggest that rhIL-11 may have multiple effects on the gastrointestinal epithelium, depending on the state of the tissue. rhIL-11 may block the proliferation of normal undamaged epithelial cells and so protect from cytotoxic damage while enhancing proliferation following injury.
In a murine model of bowel ischemia, pretreatment with IL-11 decreased mortality and morbidity. 61 In a murine model of short bowel syndrome, treatment with IL-11 ameliorated the nutritional deficits of decreased absorptive capacity by stimulating intestinal epithelial growth and function. 62, 63 These data suggest that IL-11 has a trophic effect on small intestinal enterocytes, causing cell proliferation and increased mucosal thickness. Epidermal growth factor, which was used for comparison, has a more generalized effect on intestine causing proliferation of both enterocytes and myocytes. These in vivo findings seem to be in contradiction to the cell cycle inhibition seen in the in vitro studies. Most probably this reflects the interaction of different cytokines and growth factors in vivo, when the mucosal epithelium is damaged. Taken together, the effect of rhIL-11 on damaged epithelium may be to promote proliferation and so accelerate healing. In addition, maintenance of gastrointestinal integrity protects the organism from bacterial translocation.
Acute phase response
In vitro hepatocytes rhIL-11 has been shown to induce gene expression in hepatocyte cell lines and primary rat hepatocyte cultures. Treatment of primary rat hepatocytes and a rat hepatoma cell line, H-35, with rhIL-11 induced the production of type 2 acute phase proteins, including thiostatin, fibrinogen, and ␣ 1 -antitrypsin. 64 Dexamethasone synergized with rhIL-11 to increase the production of the type 2 acute phase proteins. rhIL-11 also enhanced the IL-1-induced production of the type 1 acute phase proteins, including complement C3, ␣ 1 -acid glycoprotein, haptoglobin, and hemopexin. In other studies, rhIL-11 treatment of primary cultures of rat hepatocytes induced the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) and metallothionein. 65 Matrix metalloproteinases are involved in tissue destruction during inflammation. Metallothionein is a cysteine-rich metal-binding protein which is induced early during an acute phase response. Elevated levels of metallothionein may function to sequester zinc from the plasma and so limit zinc loss from damaged tissues. Treatment of the human hepatoma cell line, HepG2, increased the levels of heme oxygenase mRNA. 66 Heme oxygenase, the rate limiting enzyme in heme catabolism, has been implicated in protection against oxidative stress and resolution of acute inflammation.
Acute phase response in vivo
Serum concentrations of acute phase proteins (fibrinogen, creactive protein, ferritin and haptoglobin) increase in patients and normal volunteers treated with IL-11. In breast cancer patients given varying doses of rhIL-11 for 14 days (10, 25, 50 and 75 g/kg/day), fibrinogen and CRP were substantially increased relative to baseline 96 h after the first dose. Levels of both acute phase reactants returned close to baseline levels 7 days after the last rhIL-11 dose. 51 Similarly, normal volunteers given 25 g/kg/day for 7 days experienced increased fibrinogen, haptoglobin and von Willebrand levels relative to baseline within 72 h of the first rhIL-11 dose. 67 In patients with Crohn's disease treated once or twice weekly with rhIL-11 for 3 to 6 weeks, fibrinogen levels initially increased and then decreased during continued dosing. Thus, the effects of exogenous rhIL-11 on acute phase protein secretion are complex, not well understood, and may not reflect the role of endogenous IL-11. These findings indicate that one response of the liver to rhIL-11 treatment is the production of a multitude of homeostatic and cyto-protective proteins.
Adipocytes and osteoclasts
rhIL-11 has been shown to block adipogenesis in a murine stromal cell line H-1/A and in a murine preadipocyte cell line 3T3-11. 68, 69 The inhibitory effect of IL-11 on adipogenesis is believed to be mediated by IL-11 via the activation of Srcfamily protein tyrosine kinases and phosphatidylinositol 3-kinase in 3T3-L1 mouse preadipocytes. 70 rhIL-11 increases the number of osteoclasts and raises the calcium concentration in the medium of neonatal murine calvaria organ culture. 71 In a calvaria culture system, IL-11-mediated bone resorption was identified as operating through PGE 2 and was inhibited by cyclooxygenase inhibitors (eg indomethacin, NS-398 and dexamethasone). The addition of exogenous PGE 2 overcame the inhibitory effect of cyclooxygenase inhibitors and promoted bone resorption. 72 However, when tested in ovariectomized rats, rhIL-11 did not have deleterious effects on bone mineral density or bone remodeling. 73 IL-11 may contribute to the maintenance of a bone marrow microenvironment in affecting structural, nutritional, and proliferative systems.
Chondrocytes and synoviocytes
The capacity of isolated rheumatoid synovial cells (RSC) to produce IL-11, and the effect of indomethacin, dexamethasone and IFN-␥ on IL-11 production in RSC was studied in cell cultures. 74 The results suggest that the production of IL-11 by rheumatoid synovia was differentially regulated by PGE2 and IFN-␥. Treatment of the RSC cultures with indomethacin or dexamethasone decreased the level of IL-11 production. IL-11 has also been shown to be produced in arthritic synovial tissue culture. 75 Neutralization of IL-11 activity with antibody increased the production of TNF␣ and inhibition of IL-11 and IL-10 increased TNF␣ production greater than inhibition of either cytokine alone. rhIL-11 has also been shown to increase tissue inhibitor of metalloproteinase-1 (TIMP-1) from human articular chondrocytes and synoviocytes. 35 These results suggest that IL-11 may play a protective role in joint destruction during inflammatory disease.
Macrophages
In addition to its hematopoietic activities, IL-11 can downregulate macrophage effector function through the inhibition of TNF-␣, IL-1␤, IL-12, and NO production. [76] [77] [78] The antiinflammatory activity of rhIL-11 on activated macrophages is due, in part, to suppression of pro-inflammatory cytokine gene expression. 21, 78 This inhibition correlates with a block to nuclear translocation of NF-B, a transcription factor, and an increase in the cytoplasmic levels of the NF-B inhibitory proteins, IB-␣ and IB-␤. 21 The biological activity of rhIL-11 on macrophages is direct and independent of other anti-inflammatory molecules such as IL-10 and TGF-␤1. Consistent with the in vitro data, in an in vivo murine model of endotoxemia, rhIL-11 also down-regulated serum levels of LPS-induced proinflammatory cytokines, including TNF␣ and IL-1␤. 76 Thus, similar to but distinct from IL-10 and TGF-␣␤, rhIL-11 acts as an anti-inflammatory cytokine through modulation of macrophage effector cell function.
Neutrophils
IL-11 accelerates recovery of peripheral blood neutrophils and platelets in rodents, normal volunteers, and patients recovering from chemotherapy. 79 rhIL-11 does not affect the functions of purified human neutrophils in vitro. 80 This suggests that treatment with rhIL-11 will not compromise innate immunity.
B cells and T cell (lymphocytes)
In murine spleen cultures, rhIL-11 increased the number of clones producing sheep red blood cell-specific antibody. 1, 44 Depletion of CD4 + but not CD8 + helper T cells completely abrogated the ability of rhIL-11 to enhance the antibody response, suggesting that stimulation was mediated at least in part, indirectly through effects on T cells. In primary cultures of bone marrow derived from 5-FU-treated mice, rhIL-11 in combination with SCF or IL-4 supported the maintenance of B lymphoid potential. IL-4 in combination with rhIL-11 reversed the inhibition of early B cell development by IL-3 in primary bone marrow cultures. 81 In a human culture system, rhIL-11 had no effect on purified B cells or B cells stimulated with a T cell-independent B cell mitogen. However, rhIL-11 enhanced IgM and IgG production when B cells were cultured with T cells, monocytes and pokeweed mitogen. 82 These results suggest that rhIL-11 can promote accessory celldependent B cell differentiation. In a murine model of T cell differentiation, rhIL-11 polarized differentiation to the Th 2 phenotype (Trepicchio, WL et al, unpublished). rhIL-11 increased secretion of IL-4 and IL-5 and decreased secretion of IL-12.
Models of inflammation
The ability of rhIL-11 to attenuate pro-inflammatory cytokine production, modulate the immune and acute phase response, and promote mucosal repair correlates with its ability to reduce inflammation and tissue damage in a variety of experimental animal models of acute and chronic inflammatory bowel disease and systemic inflammation. rhIL-11 treatment reduces the clinical signs and histologic lesions of chronic colitis in transgenic rats expressing the human major histocompatibility complex (MHC) class I allele, HLA-B27. 83 RT-PCR analysis of colonic RNA revealed that treatment with rhIL-11 down-regulated expression of pro-inflammatory cytokines including TNF-␣, IL-1␤ and IFN-␥. 84 rhIL-11 also reduced the level of myeloperoxidase activity in the cecum, indicating reduced inflammation. After stimulation in vitro with anti-CD3 antibody, spleen cell cultures derived from rhIL-11-treated rats produced less IFN-␥, TNF-␣ and IL-2 than cultures derived from vehicle-treated rats. 84 These molecular and cellular effects correlated with the amelioration of disease, as measured by stool character and histologic lesion scores. Treatment with rhIL-11 also modulates acute colonic injury in the acetic acid-induced colitis mode 85 and TNBS-induced colitis. 86, 87 Additional animal studies have demonstrated the effects of rhIL-11 on intestinal mucosa, following bowel ischemia and in a model of short bowel syndrome. In a murine model of ischemic bowel necrosis, prophylactic treatment with rhIL-11 decreased mortality and enhanced recovery of the intestinal mucosa. 61 Following 90% resection of the small bowel, rhIL-11 had a trophic effect as measured by villus height and crypt cell mitosis. 62, 63 Studies in transgenic animals over-expressing IL-11 in the lung demonstrated that IL-11 markedly diminishes hyperoxic lung injury. The observed protection was associated with small changes in lung antioxidants, diminished hyperoxiainduced IL-1␣ and TNF␣ production, and markedly suppressed hyperoxia-induced DNA fragmentation. 88 In a murine model of radiation-induced thoracic injury, rhIL-11 treatment increased survival and reduced TNF␣ expression in the lung. 77 In a murine model of graft-versus-host disease (GVHD), rhIL-11 prevented acute GVHD and polarized the T cell response to a TH2 phenotype. 89 rhIL-11 reduced serum levels of IFN␥ and TNF␣ while preventing small bowel damage.
In a murine model of toxic shock syndrome, pretreatment with rhIL-11 before administration of a lethal dose of S. aureus enterotoxin B galactosamine protected against mortality. 90 Pretreatment with rhIL-11 reduced serum levels of proinflammatory cytokines, including TNF␣, IL-1␣ and IFN-␥, following LPS administration in a murine model of endotoxemia. 76 In a rabbit model of endotoxemia, rhIL-11 administration prevented LPS-induced hypotension and gastrointestinal damage. 91 The biological activity of rhIL-11 has been studied in a rat model of gram-negative sepsis. 92 In this model, which mimics the clinical situation of infection following myelosuppressive therapy, rats are colonized with Pseudomonas aeruginosa and rendered neutropenic by treatment with cyclophosphamide. rhIL-11 was administered following the onset of fever. Treatment with rhIL-11 increased survival from 0% in vehicletreated animals to 40%. When rhIL-11 was given in combination with an antimicrobial agent, ciprofloxin, survival rose from 60% with ciprofloxin treatment alone to 100% with combination therapy. rhIL-11-treated animals had reduced quantitative levels of bacterial infection in the lung, reduced intestinal mucosal damage, and reduced serum levels of TNF␣ compared with vehicle-treated animals. Taken together, these studies suggest that rhIL-11 treatment may ameliorate a systemic inflammatory response and associated tissue damage by effects on both macrophage and T cell effector functions.
Kidney
IL-11 may have direct effects on renal solute and water transport. IL-11 causes volume retention within 5 to 8 h after subcutaneous injection. In an isolated perfused kidney system, it was demonstrated that IL-11 was almost completely filtered by glomerular filtration and reabsorbed by the kidney. 93 It is thus conceivable that IL-11 is metabolized and inactivated by the kidney. It is unclear at present whether the effect of IL-11 on salt and water homeostasis is a direct effect of IL-11 on the kidney or an indirect effect activated through a cardiovascular mechanism.
Clinical studies
Clinical pharmacology and rhIL-11 disposition
The clinical pharmacology of rhIL-11 has been studied in normal volunteers and patients. rhIL-11 is rapidly eliminated after intravenous injection (t 1/2 between 1.5 and 2 h). Subcutaneously administered rhIL-11 exhibits an absorption-limited disposition, with a mean residence time between 10 and 15 h.
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The bioavailability of rhIL-11 is between 60 and 80%. 94 rhIL-11 is predominantly cleared renally, as indicated by a 60% increase in area under the curve (AUC) in dialysis patients 95 and animal experiments that demonstrate both renal filtration and tubular reabsorption of rhIL-11. 93 In patients and normal volunteers, IL-11 was found to cause a dilutional anemia, which was reversible upon cessation of treatment. Volume retention was demonstrated in normal volunteers as a result of renal sodium retention. Whether this effect reflects a direct renal mechanism of rhIL-11 or is mediated via other sodium-conserving mechanisms (eg the renin-angiotensin system) is unclear at this time. 96, 97 The kidney is also the major pathway of IL-11 clearance; IL-11 is removed by glomerular filtration and completely reabsorbed at the proximal tubule. The function of IL-11 at the proximal tubule is unknown and may be a general tubular protein conserving mechanism. Dialysis-dependent humans and Anephric experimental animals have a delayed clearance of rhIL-11. 95 Inflammatory disease rhIL-11 is currently under investigation for a variety of inflammatory conditions including Crohn's disease, 98 rheumatoid arthritis and psoriasis. In these clinical studies, rhIL-11 is given subcutaneously once or twice per week for up to 3 months. The results of these studies have been encouraging and have led to later phases of development.
Summary
Many studies have identified the pleiotropic properties of rhIL-11. IL-11 is secreted by mesenchymal cells in the bone marrow microenvironment, with direct effects on hematopoietic precursor cells, macrophages, adipocytes, epithelial cells and T cells. rhIL-11 induces acute phase protein secretion from the liver, which may contribute to its anti-inflammatory activity in vivo. In models of systemic inflammatory response, rhIL-11 reduced the production of pro-inflammatory cytokines and increased survival. In models of acute gastrointestinal mucosal injury, rhIL-11 increased survival and reduced mucosal damage. rhIL-11 ameliorated gross and histologic damage in models of acute and chronic colitis. rhIL-11 has direct effects on intestinal epithelial cells to modulate growth and gene expression. Several in vivo models have shown that rhIL-11 has trophic effects and can reduce apoptosis in damaged intestinal epithelium, resulting in protection and healing of the mucosa. Maintenance of gastrointestinal mucosal integrity reduces the risk of bacterial translocation and sepsis. The antiinflammatory activity of rhIL-11 acts at multiple levels of the inflammatory response. rhIL-11 has direct effects on activated macrophages to reduce the production of pro-inflammatory cytokines, including TNF␣ and IL-1␤. Modulation of macrophage function is mediated through inhibition of the transcription factor NF-B. NF-B is involved in the transcriptional activation of genes for many pro-inflammatory cytokines and adhesion molecules. Because of this, NF-B is considered to play an important role in many inflammatory diseases and has become a target of anti-inflammatory therapies. rhIL-11 also has direct effects on hepatocyte gene expression to produce proteins important for homeostasis and tissue protection. In hepatocyte culture, rhIL-11 induces expression of acute phase proteins, TIMP-1, and heme oxygenase. In vivo treatment with rhIL-11 is associated with induction of an acute phase response, including elevation of fibrinogen and von Willebrand factor. Based on this assessment, rhIL-11 should offer multiple benefits for patients treated with cytoablative therapies and prove of clinical value in the therapy of inflammatory diseases.
